Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37516
Title: European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology
Authors: Aktaa, Suleman
Gencer, Baris
Arbelo, Elena
Davos, Constantinos H.
Desormais, Ileana
Hollander, Monika
Abreu, Ana
Ambrosetti, Marco
Back, Maria
Carballo, David
Crawford, Carolyn
Deaton, Christi
DENDALE, Paul 
Eijsvogels, Thijs M. H.
Galbraith, Mary
Piepoli, Massimo Francesco
Salzwedel, Annett
Smulders, Yvo
Wilhelm, Matthias
Biondi-Zoccai, Giuseppe
Mach, Francois
Visseren, Frank L. J.
Gale, Chris P.
Issue Date: 2021
Publisher: OXFORD UNIV PRESS
Source: European Journal of Preventive Cardiology, 29 (7) , p. 1060 -1071
Abstract: Aims To develop a set of quality indicators (QIs) for the evaluation of the care and outcomes for atherosclerotic cardiovascular disease (ASCVD) prevention. Methods and results The Quality Indicator Committee of the European Society of Cardiology (ESC) formed the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with Task Force members of the 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice and the European Association of Preventive Cardiology (EAPC). We followed the ESC methodology for QI development, which involved (i) the identification of the key domains of care for ASCVD prevention by constructing a conceptual framework of care, (ii) the development of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of QIs using a modified Delphi method, and (iv) the evaluation of the feasibility of the developed QIs. In total, 17 main and 14 secondary QIs were selected across six domains of care for ASCVD prevention: (i) structural framework, (ii) risk assessment, (iii) care for people at risk for ASCVD, (iv) care for patients with established ASCVD, (v) patient education and experience, and (vi) outcomes. Conclusion We present the 2021 ESC QIs for Cardiovascular Disease Prevention, which have been co-constructed with EAPC using the ESC methodology for QI development. These indicators are supported by evidence from the literature, underpinned by expert consensus and aligned with the 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice to offer a mechanism for the evaluation of ASCVD prevention care and outcomes.
Notes: Aktaa, S (corresponding author), Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Leeds LS2 9LU, W Yorkshire, England.; Aktaa, S (corresponding author), Univ Leeds, Leeds Inst Data Analyt, Leeds LS2 9LU, W Yorkshire, England.; Aktaa, S (corresponding author), Leeds Teaching Hosp NHS Trust, Dept Cardiol, Leeds, W Yorkshire, England.
s.aktaa@leeds.ac.uk
Keywords: Cardiovascular disease;Atherosclerosis;Preventive cardiology;Quality indicators;Clinical practice guidelines
Document URI: http://hdl.handle.net/1942/37516
ISSN: 2047-4873
e-ISSN: 2047-4881
DOI: 10.1093/eurjpc/zwab160
ISI #: WOS:000790107600001
Rights: The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.
Category: A1
Type: Journal Contribution
Validations: ecoom 2023
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
OP-EURJ210449 1060..1071.pdfPublished version942.7 kBAdobe PDFView/Open
Show full item record

WEB OF SCIENCETM
Citations

28
checked on Apr 30, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.